

# Sarah P Sherlock

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10074499/publications.pdf>

Version: 2024-02-01

4  
papers

108  
citations

1684188

5  
h-index

2053705

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

156  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Domagrozumab (PF-06252616), an Antimyostatin Monoclonal Antibody, in Healthy Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 484-497.	1.6	41
2	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. <i>Neuromuscular Disorders</i> , 2020, 30, 492-502.	0.6	40
3	Quantitative muscle MRI biomarkers in Duchenne muscular dystrophy: cross-sectional correlations with age and functional tests. <i>Biomarkers in Medicine</i> , 2021, 15, 761-773.	1.4	12
4	Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. <i>Journal of Neurology</i> , 2022, 269, 4421-4435.	3.6	6